![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MPC2 |
Gene summary for MPC2 |
![]() |
Gene information | Species | Human | Gene symbol | MPC2 | Gene ID | 25874 |
Gene name | mitochondrial pyruvate carrier 2 | |
Gene Alias | BRP44 | |
Cytomap | 1q24.2 | |
Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | A0A024R8Z5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
25874 | MPC2 | GSM4909281 | Human | Breast | IDC | 9.08e-26 | 6.66e-01 | 0.21 |
25874 | MPC2 | GSM4909285 | Human | Breast | IDC | 8.01e-12 | 4.05e-01 | 0.21 |
25874 | MPC2 | GSM4909286 | Human | Breast | IDC | 2.53e-02 | 3.81e-03 | 0.1081 |
25874 | MPC2 | GSM4909287 | Human | Breast | IDC | 6.91e-12 | 4.84e-01 | 0.2057 |
25874 | MPC2 | GSM4909288 | Human | Breast | IDC | 2.51e-03 | 2.55e-01 | 0.0988 |
25874 | MPC2 | GSM4909291 | Human | Breast | IDC | 2.38e-08 | 4.73e-01 | 0.1753 |
25874 | MPC2 | GSM4909293 | Human | Breast | IDC | 1.69e-82 | 1.18e+00 | 0.1581 |
25874 | MPC2 | GSM4909294 | Human | Breast | IDC | 2.66e-06 | 2.51e-01 | 0.2022 |
25874 | MPC2 | GSM4909296 | Human | Breast | IDC | 2.30e-07 | 5.90e-02 | 0.1524 |
25874 | MPC2 | GSM4909297 | Human | Breast | IDC | 3.02e-14 | -2.90e-01 | 0.1517 |
25874 | MPC2 | GSM4909306 | Human | Breast | IDC | 4.71e-08 | 4.52e-01 | 0.1564 |
25874 | MPC2 | GSM4909307 | Human | Breast | IDC | 2.67e-15 | 5.22e-01 | 0.1569 |
25874 | MPC2 | GSM4909308 | Human | Breast | IDC | 9.24e-51 | 8.69e-01 | 0.158 |
25874 | MPC2 | GSM4909311 | Human | Breast | IDC | 1.52e-29 | -1.38e-01 | 0.1534 |
25874 | MPC2 | GSM4909312 | Human | Breast | IDC | 1.78e-30 | 5.90e-01 | 0.1552 |
25874 | MPC2 | GSM4909313 | Human | Breast | IDC | 2.73e-07 | 7.10e-02 | 0.0391 |
25874 | MPC2 | GSM4909315 | Human | Breast | IDC | 2.07e-17 | 5.50e-01 | 0.21 |
25874 | MPC2 | GSM4909316 | Human | Breast | IDC | 1.59e-13 | 5.93e-01 | 0.21 |
25874 | MPC2 | GSM4909317 | Human | Breast | IDC | 5.58e-12 | 5.08e-01 | 0.1355 |
25874 | MPC2 | GSM4909318 | Human | Breast | IDC | 2.21e-12 | 6.68e-01 | 0.2031 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003577313 | Thyroid | ATC | insulin secretion involved in cellular response to glucose stimulus | 34/6293 | 73/18723 | 1.45e-02 | 4.98e-02 | 34 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541523 | Breast | IDC | Diabetic cardiomyopathy | 67/867 | 203/8465 | 3.17e-19 | 8.59e-18 | 6.43e-18 | 67 |
hsa0541533 | Breast | IDC | Diabetic cardiomyopathy | 67/867 | 203/8465 | 3.17e-19 | 8.59e-18 | 6.43e-18 | 67 |
hsa0541543 | Breast | DCIS | Diabetic cardiomyopathy | 65/846 | 203/8465 | 1.81e-18 | 4.87e-17 | 3.59e-17 | 65 |
hsa0541553 | Breast | DCIS | Diabetic cardiomyopathy | 65/846 | 203/8465 | 1.81e-18 | 4.87e-17 | 3.59e-17 | 65 |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa054152 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
hsa054153 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
hsa054154 | Colorectum | MSS | Diabetic cardiomyopathy | 106/1875 | 203/8465 | 2.47e-21 | 1.62e-19 | 9.92e-20 | 106 |
hsa054155 | Colorectum | MSS | Diabetic cardiomyopathy | 106/1875 | 203/8465 | 2.47e-21 | 1.62e-19 | 9.92e-20 | 106 |
hsa054158 | Colorectum | FAP | Diabetic cardiomyopathy | 70/1404 | 203/8465 | 2.62e-10 | 2.18e-08 | 1.33e-08 | 70 |
hsa054159 | Colorectum | FAP | Diabetic cardiomyopathy | 70/1404 | 203/8465 | 2.62e-10 | 2.18e-08 | 1.33e-08 | 70 |
hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa0541538 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa0541514 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0541515 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0541522 | Liver | HCC | Diabetic cardiomyopathy | 151/4020 | 203/8465 | 2.72e-15 | 1.01e-13 | 5.63e-14 | 151 |
hsa0541532 | Liver | HCC | Diabetic cardiomyopathy | 151/4020 | 203/8465 | 2.72e-15 | 1.01e-13 | 5.63e-14 | 151 |
hsa0541542 | Liver | Cyst | Diabetic cardiomyopathy | 34/339 | 203/8465 | 6.93e-13 | 2.50e-11 | 2.06e-11 | 34 |
hsa0541552 | Liver | Cyst | Diabetic cardiomyopathy | 34/339 | 203/8465 | 6.93e-13 | 2.50e-11 | 2.06e-11 | 34 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MPC2 | SNV | Missense_Mutation | c.175G>A | p.Asp59Asn | p.D59N | O95563 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
MPC2 | SNV | Missense_Mutation | novel | c.208N>A | p.Ala70Thr | p.A70T | O95563 | protein_coding | tolerated(0.21) | benign(0.034) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MPC2 | SNV | Missense_Mutation | novel | c.239T>C | p.Phe80Ser | p.F80S | O95563 | protein_coding | deleterious(0.01) | benign(0.097) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MPC2 | SNV | Missense_Mutation | c.303C>A | p.Phe101Leu | p.F101L | O95563 | protein_coding | tolerated(1) | benign(0.011) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
MPC2 | SNV | Missense_Mutation | c.303N>A | p.Phe101Leu | p.F101L | O95563 | protein_coding | tolerated(1) | benign(0.011) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MPC2 | SNV | Missense_Mutation | novel | c.235G>T | p.Gly79Trp | p.G79W | O95563 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0VI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MPC2 | SNV | Missense_Mutation | c.303N>A | p.Phe101Leu | p.F101L | O95563 | protein_coding | tolerated(1) | benign(0.011) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
MPC2 | SNV | Missense_Mutation | novel | c.311G>A | p.Gly104Glu | p.G104E | O95563 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MPC2 | insertion | Frame_Shift_Ins | novel | c.278dupA | p.Asn93LysfsTer8 | p.N93Kfs*8 | O95563 | protein_coding | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
MPC2 | SNV | Missense_Mutation | novel | c.28C>T | p.Arg10Trp | p.R10W | O95563 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-G3-AAV7-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |